Sumatriptan

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Sumatriptan
   1. Pharmacist Assessment Report
   2. Sumatriptan: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Sumatriptan: Known uses and market status in Canada

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Sumatriptan. Every candidate that can be traced to a source is already a known use, so there is currently no new predicted indication. The one known use is listed below with its source.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs on record: at least 20)
Number of DINs	at least 20

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
migraine with brainstem aura	licence in another country; approved indication: migraine

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02256428	PMS-SUMATRIPTAN		Valid
02545357	JAMP SUMATRIPTAN		Valid
02268906	MYLAN-SUMATRIPTAN		Valid
02286823	TEVA-SUMATRIPTAN DF		Valid
02385589	SUMATRIPTAN DF		Valid
02286548	SUMATRIPTAN		Valid
02268388	APO-SUMATRIPTAN		Valid
02324660	SUMATRIPTAN		Valid
02545365	JAMP SUMATRIPTAN		Valid
02546043	SUMATRIPTAN		Valid
02546035	SUMATRIPTAN		Valid
02545292	JAMP SUMATRIPTAN DF		Valid
02286831	TEVA-SUMATRIPTAN DF		Valid
02286521	SUMATRIPTAN		Valid
02324652	SUMATRIPTAN		Valid
02268396	APO-SUMATRIPTAN		Valid
02230418	IMITREX		Valid
02256436	PMS-SUMATRIPTAN		Valid
02212188	IMITREX		Valid
02286815	TEVA-SUMATRIPTAN DF		Valid

Only part of the licence list is held in the data; the list may be incomplete.

Safety Considerations

Contraindication-related conditions from the knowledge graph (these come from drug–disease contraindication links in the knowledge graph, not from package insert text):

• Cardiovascular: coronary artery disease, myocardial infarction, coronary thrombosis, heart disease, congestive heart failure, hypertension, peripheral vascular disease, intermittent claudication
• Cerebrovascular: stroke, cerebral infarction, cerebrovascular disorder
• Hepatic and renal: liver disease, liver failure, kidney disease
• Others: epilepsy, diabetes mellitus, diabetic ketoacidosis, obesity, blood coagulation disease, haemoglobinopathy, anaemia, gallbladder disease, substance abuse/dependence

Drug Interactions (100 interactions recorded; main ones shown):

• Major: dexfenfluramine, fenfluramine, lorcaserin, sibutramine (serotonergic agents); dolasetron, granisetron, ondansetron, palonosetron (5-HT3 antagonists)
• Moderate: morphine, liposomal morphine
• Several others have an unclassified severity level, including pantoprazole, omeprazole, lansoprazole, metformin, doxycycline and cimetidine.

Package insert warnings and contraindications were not available for this report; please refer to the Health Canada package insert.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---